A comparative evaluation of the dopamine D2/3 agonist radiotracer [11C](−)-N-propyl-norapomorphine and antagonist [11C] raclopride to measure amphetamine …
…, BJ Lopresti, ND Velasquez, MA May… - … of Pharmacology and …, 2010 - ASPET
(−)-N-Propyl-norapomorphine (NPA) is a full dopamine D 2/3 receptor agonist, and [ 11 C]NPA
is a suitable radiotracer to image D 2/3 receptors configured in a state of high affinity for …
is a suitable radiotracer to image D 2/3 receptors configured in a state of high affinity for …
Analysis of bacteriophage deoxyribonucleic acid sequences methylated by host-and R-factor-controlled enzymes
MS May, S Hattman - Journal of bacteriology, 1975 - Am Soc Microbiol
Phages lambda and fd were propagated in Escherichia coli strains that have either host K-12
or the N-3 R-factor deoxyribonucleic acid-cytosine methylase activity. Pyrimidine tracts …
or the N-3 R-factor deoxyribonucleic acid-cytosine methylase activity. Pyrimidine tracts …
In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers
…, NS Mason, M Himes, MA May… - American Journal of …, 2012 - Am Psychiatric Assoc
Objective: Positron emission tomography (PET) imaging studies in cocaine abusers have
shown that low dopamine release in the striatum following an amphetamine challenge is …
shown that low dopamine release in the striatum following an amphetamine challenge is …
Positron emission tomography imaging of dopamine D2/3 receptors in the human cortex with [11C]FLB 457: Reproducibility studies
R Narendran, NS Mason, MA May, CM Chen… - Synapse, 2011 - Wiley Online Library
… , as the baseline and postamphetamine scan in our previous study were separated by 3 h,
there was concern that the FLB 457 mass carried over from the baseline PET scan may have …
there was concern that the FLB 457 mass carried over from the baseline PET scan may have …
Evaluation of dopamine D2/3specific binding in the cerebellum for the positron emission tomography radiotracer [11C]FLB 457: Implications for measuring cortical …
…, NS Mason, CM Chen, M Himes, P Keating, MA May… - Synapse, 2011 - Wiley Online Library
In a recent positron emission tomography (PET) study, we demonstrated the ability to measure
amphetamine‐induced dopamine (DA) release in the human cortex with the DA D 2/3 …
amphetamine‐induced dopamine (DA) release in the human cortex with the DA D 2/3 …
Imaging of dopamine D2/3 agonist binding in cocaine dependence: A [11C]NPA positron emission tomography study
…, BJ Lopresti, ML Himes, CM Chen, MA May… - Synapse, 2011 - Wiley Online Library
Objective: Positron emission tomography (PET) studies performed with [ 11 C]raclopride
have consistently reported lower binding to D 2/3 receptors and lower amphetamine‐induced …
have consistently reported lower binding to D 2/3 receptors and lower amphetamine‐induced …
Deoxyribonucleic acid-cytosine methylation by host-and plasmid-controlled enzymes
MS May, S Hattaman - Journal of Bacteriology, 1975 - Am Soc Microbiol
Deoxyribonucleic acid (DNA)-cytosine methylation specified by the wild-type Escherichia coli
K 12 mec+ gene and by the N-3 drug resistance (R) factor was studied in vivo and in vitro. …
K 12 mec+ gene and by the N-3 drug resistance (R) factor was studied in vivo and in vitro. …
Recession and anterior transposition of the inferior oblique for treatment of superior oblique palsy
MA May, GR Beauchamp, RL Price - Graefe's archive for clinical and …, 1988 - Springer
We evaluated the effectiveness of inferior oblique recession with anterior transposition in
treating 12 patients with superior oblique palsy. Mean decreases of hypertropia measured 17 …
treating 12 patients with superior oblique palsy. Mean decreases of hypertropia measured 17 …
New drug development by United States pharmaceutical firms: With analyses of trends in the acquisition and origin of drug candidates, 1963–1979
WM Wardell, MS May… - Clinical Pharmacology & …, 1982 - Wiley Online Library
The average number of self‐originated new chemical entities (NCEs) first tested in man by 39
United States‐owned pharmaceutical firms in the 3‐year period from 1977 to 1979 was 26 …
United States‐owned pharmaceutical firms in the 3‐year period from 1977 to 1979 was 26 …
New drug development during and after a period of regulatory change: Clinical research activity of major united states pharmacxeutical firms, 1958 to 1979
MS May, WM Wardell, L Lasagna - Clinical Pharmacology & …, 1983 - Wiley Online Library
The 1962 drug amendments fundamentally changed the way in which US pharmaceutical
firms could test new drugs in man and receive New Drug Application (NDA) approval. …
firms could test new drugs in man and receive New Drug Application (NDA) approval. …